Sign In
Buy MLTX
$19.02
-0.340 (-1.76%)
At Close: Jul 24, 2026
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of December 15, 2025 in MoonLake Lawsuit - MLTX
09:00am, Thursday, 04'th Dec 2025
NEW YORK , Dec. 4, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX). Shareholders who purchased shares of MLTX during t
MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MLTX
07:52am, Thursday, 04'th Dec 2025
LOS ANGELES , Dec. 4, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against MoonLake Immunotherapeutics ("MoonLake " or "the Company") (NASDAQ: MLTX ) for violatio
MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm
07:51am, Thursday, 04'th Dec 2025
LOS ANGELES , Dec. 4, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against MoonLake Immunotherapeutics ("Moo
New York, New York--(Newsfile Corp. - December 3, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) betwe
MoonLake Immunotherapeutics Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm for More Information – MLTX
04:21pm, Wednesday, 03'rd Dec 2025
NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX).
New York, New York--(Newsfile Corp. - December 3, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ: ML
MoonLake's (MLTX) SLK Efficacy Claims Under Scrutiny After 90% Plunge; Focus on Nanobody vs. BIMZELX Superiority- Hagens Berman
03:05pm, Wednesday, 03'rd Dec 2025
MLTX Investor with Losses Encourages to Contact Firm by Dec. 15 Deadline SAN FRANCISCO , Dec. 3, 2025 /PRNewswire/ -- Global plaintiffs' rights law firm Hagens Berman reminds investors that the deadli
BENSALEM, Pa. , Dec. 03, 2025 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded
NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds MoonLake Immunotherapeutics (“MoonLake” or the “Company”) (NASDAQ:
New York, New York--(Newsfile Corp. - December 3, 2025) - Bronstein, Gewirtz and Grossman, LLC, a nationally recognized law firm,
MoonLake Immunotherapeutics investors that lost money are notified to contact BFA before the December 15, 2025 securities fraud class action deadline.
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics
07:20pm, Tuesday, 02'nd Dec 2025
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in MoonLake to Contact Him Directly to Discuss Their Options If you purchased or acquire
MLTX Deadline: MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit
05:52pm, Tuesday, 02'nd Dec 2025
NEW YORK , Dec. 2, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024
Bragar Eagel & Squire, P.C. Urges Investors of Cepton, and MoonLake to Inquire About Their Rights Before Upcoming Deadlines
05:29pm, Tuesday, 02'nd Dec 2025
NEW YORK, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stoc
MLTX Lawsuit: Hagens Berman Scrutinizing MoonLake's SLK Efficacy Claims After 90% Plunge; Focus on Nanobody vs. BIMZELX Superiority
05:25pm, Tuesday, 02'nd Dec 2025
Lead Partner Reed Kathrein Investigating Alleged Undisclosed Truth: Did SLK's Nanobody Structure Truly Confer a Superior Clinical Benefit Over Monoclonal Antibodies? Lead Partner Reed Kathrein Investi
